- |||||||||| levetiracetam / Generic mfg.
Retrospective data, Review, Journal: Levetiracetam versus Phenobarbitone for Management of Neonatal Seizures: A Systematic Review and Meta-analysis. (Pubmed Central) - Dec 10, 2024
With the limitation of very-low certainty evidence, the results of this systematic review suggest that levetiracetam may be non-inferior to phenobarbitone for managing neonatal seizures. Considering a better safety profile and marginally better neurodevelopment in the short term, levetiracetam may be considered an initial choice for managing neonatal seizures.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Efficacy and Prognosis of Blinatumomab As a Bridge Therapy for Hematopoietic Stem Cell Transplantation for B-ALL () - Dec 7, 2024 - Abstract #ASH2024ASH_9209;
With a median follow-up of 11 months, 41 patients had 1-year OS and PFS of 77.9% and 76.9% , respectively, and 10 MRD positive patients had 1-year OS and PFS of 66.4% and 65.6% , respectively, the 1-year OS and PFS of 31 MRD negative patients were 82.4% and 82% , respectively. Nine patients died after transplantation, including 9 from severe infection, 2 from GVHD and 3 from relapse.Result : Bridging transplantation after 7 days of continuous use of Blinatumoma has been shown to improve remission rates and long-term survival in patients with B-ALL, particularly in MRD-negative patients.
- |||||||||| Tafinlar (dabrafenib) / Novartis
BRAFV600E-Mutated Histiocytic Sarcoma Presenting on a Background of Clonal Cytopenia Responsive to Dabrafenib: Case Report and Review of the Literature () - Dec 7, 2024 - Abstract #ASH2024ASH_8692;
He was treated with a weaning course of dexamethasone 8 mg dailyand urgent radiotherapy (8Gy single fraction) to the base of skull lesion...Levetiracetam 500 mg twice a daywas given as anti-epileptic prophylaxis.Over the following week, his condition rapidly improved, he became pain-free, conversant and able to feed himself although he remained bed-bound...Generally, these treatments were well tolerated and associated with manageable toxicity. Although responses were not durable and 50% of cases had progressed within 12 months,the advantage of a non-toxic regimen is clear when preserving quality of life is the goal of therapy, as in this case.Note : The use of Dabrafenib for histiocytic sarcoma is off-label
- |||||||||| inosine pranobex / Generic mfg., levetiracetam / Generic mfg.
Journal: Contemporary Treatment Practices for Subacute Sclerosing Panencephalitis: A Nationwide Survey Among Adult and Pediatric Neurologists in India. (Pubmed Central) - Dec 6, 2024
Although responses were not durable and 50% of cases had progressed within 12 months,the advantage of a non-toxic regimen is clear when preserving quality of life is the goal of therapy, as in this case.Note : The use of Dabrafenib for histiocytic sarcoma is off-label While SSPE remains a vaccine-preventable illness and the focus should be on prevention through vaccination, there is an unmet urgent need among Indian neurologists for better-defined treatment strategies for patients with SSPE.
- |||||||||| Diacomit (stiripentol) / Biocodex, Meiji Seika, Fintepla (low-dose fenfluramine) / UCB
Journal: Antiseizure medication prescribing in people with Dravet syndrome: An analysis of real-time administrative data. (Pubmed Central) - Dec 5, 2024
Even though stiripentol and fenfluramine are considered second-line treatments for Dravet syndrome, we found they were prescribed less frequently than medicines considered third-line or beyond. These findings raise concern for underutilization of new antiseizure medications for Dravet syndrome in the United States.
- |||||||||| levetiracetam / Generic mfg.
Journal: Dyke-Davidoff-Masson syndrome - A dainty spectrum with a diligent diagnosis. (Pubmed Central) - Dec 4, 2024
This child had a history of complex febrile seizures at 1.5 years of age and was started on levetiracetam (20 mg/kg/day)...Due to its rarity, Dyke-Davidoff-Masson syndrome may easily be missed by the treating physician. Knowledge of its radio-imaging features enables timely and accurate diagnosis, allowing appropriate management.
- |||||||||| levetiracetam / Generic mfg.
Preclinical, Journal: Preclinical validation and kinetic modelling of the SV2A PET ligand [18F]UCB-J in mice. (Pubmed Central) - Dec 4, 2024
[18F]UCB-J specificity for SV2A was confirmed through a levetiracetam blocking assay (50 to 200?mg/kg)...In conclusion, [18F]UCB-J is a selective SV2A ligand with optimal kinetics in mice. Further investigation is warranted for (pre)clinical applicability of [18F]UCB-J in synaptopathies.
- |||||||||| lacosamide / Generic mfg., levetiracetam / Generic mfg., carbamazepine / Generic mfg.
Japanese regulatory, Review, Journal: Effects of frequently prescribed antiseizure medications on motor vehicle driving performance: Narrative review based on a tiered approach for the assessment of clinically meaningful driving impairment in the Ministry of Health, Labour, and Welfare guideline. (Pubmed Central) - Dec 2, 2024
Initial administration of these five antiseizure medications may affect driving performance, warranting special attention, but the influence appears to diminish with continued use. Nevertheless, while long-term administration of these five drugs may not have a clinically meaningful effect on driving performance, safe driving is not guaranteed for each individual patient, and appropriate individualized guidance is important in clinical practice.
- |||||||||| levetiracetam / Generic mfg.
Journal: Levetiracetam and severe cutaneous adverse reactions: insights from FAERS database analysis. (Pubmed Central) - Dec 2, 2024
Concomitant medications, including phenytoin, valproate, and aspirin, were common, with some drugs indicating an increased SCAR risk when used alongside levetiracetam. The findings suggest a notable risk of SCARs associated with levetiracetam, with an emphasis on monitoring patients, particularly females and those on concomitant medications.
- |||||||||| ezogabine (XEN496) / Xenon
Preclinical, Journal: Variant-specific in (Pubmed Central) - Nov 26, 2024
Phenytoin and levetiracetam reduced the excitability of GoF cultures, while retigabine showed differential and potentially beneficial effects on cultures with both GoF and LoF variants. We conclude that in
- |||||||||| Xcopri (cenobamate) / SK Bio
Use of Cenobamate in Dravet Syndrome (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2567;
Three of our patients from different age groups experienced significant improvement in their seizure control after addition of CNB. For one of our patients, response to therapy seemed to be transient and CNB dose titration was limited by side effects.
- |||||||||| Understanding the Natural History of cyfip2-related Epilepsy (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2561;
Patients with CYFIP2-related DEE have developmental delay, epilepsy with multiple seizure types, and a hyperkinetic movement disorder. Ours is the only reported case of substantial improvement with timely treatment following initial seizure onset and prior to epileptic spasms.
- |||||||||| levetiracetam / Generic mfg., brivaracetam / Generic mfg.
Transitioning from Levetiracetam to Brivaracetam in Veterans with Medically Refractory Epilepsy (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2553;
While, generally, in adult populations, the incidence of BAEs is estimated at 13.3% of patients on LEV, only 4.35% of veterans at our institution were switched from LEV to BRV. In veterans with BAEs on LEV, switching to BRV was associated with a reduction in BAEs.
- |||||||||| Fycompa (perampanel) / Eisai, Catalyst Pharma, lamotrigine liquid oral suspension / OWP Pharma
The Use of Ketogenic Diet During Pregnancy to Treat NORSE (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2532;
KD therapy is one of a paucity of potentially effective treatments for NORSE, but in the setting of pregnancy therapeutic ketosis may not be achievable due to minimum protein requirements. Because other NORSE treatments also have teratogenic potential, a multidisciplinary discussion of the risks and benefits of all treatments, including possible short term protein restriction to maximize KD therapy, should be initiated early with family.
- |||||||||| lamotrigine liquid oral suspension / OWP Pharma
The Epilepsy Spectrum (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2511;
According to earlier ICHD-II criteria for migralepsy, a seizure occurring within 1 hour of a migraine aura applies to PJ's case (1, 2). PJ also experiences a visual aura, a trait seen in migralepsy cases (3).
- |||||||||| Selective Secondary Language Impairment in a Case of NMDA Receptor Antibody-associated Encephalitis with Temporal Lobe Seizures (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2447;
While isolated aphasia has previously been described in temporal lobe seizures (2-4), this is the first case to our knowledge of aphasia affecting primarily the secondary language in temporal lobe seizures from autoimmune encephalitis with full recovery after steroid therapy. This case highlights both the importance and challenge of early diagnostics and intervention, especially in patient populations who are recent immigrants, where language impairment and poor access to health care can have even more devastating consequences.
- |||||||||| Seizures in the Leukodystrophies Analyzed by Diagnosis and Pathogenetic Mechanism (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2443;
Patients with an astrocytopathy were more affected by seizures overall, and more often went on to develop focal epilepsy than patients with a myelinopathy. Lacosamide, levetiracetam, and zonisamide demonstrated the highest overall response rates.
- |||||||||| Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Seizure Monitoring with Combined Diary and Wearable Data - A Multicenter, Longitudinal, Observational Study (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2427;
P4
On a group level, wearable data capture seizure-related differences with daily resolution, identifying periods of higher or lower seizure susceptibility. Combining diary-based clinical and wearable data bears the potential for developing a dynamic seizure detection and prediction system with daily resolution.
- |||||||||| lorazepam / Generic mfg., levetiracetam / Generic mfg., topiramate / Generic mfg.
Screening of Conventional Anticonvulsants in an Alzheimer's Disease-associated Mouse Model (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2421;
Young adult PSEN2 KO mice were more susceptible to KA-induced seizures and SE vs WT mice. Our study demonstrates that increased seizure susceptibility in this AD-associated mouse model may be well-suited to ASM screening, thereby expanding the potential to uncover novel therapeutic treatments for seizures in AD.
- |||||||||| levetiracetam / Generic mfg.
scn8a-related Epilepsy: A Study from the Gulf Region (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2414;
All of the cohort had developmental delay and epilepsy which represent a severe spectrum of the condition. In the era of precision medicine, medication selection can depend on the type of genetic mutation.
- |||||||||| Prescribing Trends of Antiseizure Medications in Veterans with Epilepsy (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2373;
Data analysis suggests a transition towards prescribing newer ASMs. With the increase in number of female Veterans and the risk of teratogenesis with valproate, phenytoin and topiramate ECoE sites are playing an important role in educating patients and guiding the optimal treatment factoring in gender, epilepsy syndrome and age to improve patient care outcomes.
- |||||||||| levetiracetam / Generic mfg.
National Patterns of Outpatient Epilepsy-specific Medication Initiation Post-acute Ischemic Stroke (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2302;
Black/African American and Hispanic beneficiaries had a higher 90-day incidence of post-AIS ESM initiation than non-Hispanic Whites. These disparities may arise from unadjusted baseline severity, in-hospital or post-discharge care disparities, and other factors requiring further investigation.
- |||||||||| levetiracetam / Generic mfg., brivaracetam / Generic mfg.
Microsampling Methodology to Allow Self-collection of Blood in Pharmacokinetic Studies (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2290;
These disparities may arise from unadjusted baseline severity, in-hospital or post-discharge care disparities, and other factors requiring further investigation. To facilitate convenient self-collection of pharmacokinetic study samples and reduce the necessity for in-person study, we developed and validated a robust microsampling assay to measure the concentrations of three ASMs - levetiracetam (LEV), lamotrigine (LTG), and brivaracetam (BRV)
- |||||||||| levetiracetam / Generic mfg.
Management of Non-lesional Super Refractory Status Epilepticus: A Rare Case Report (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2280;
Early surgical intervention is a treatment option to be considered in SRSE. Criteria to select a patient for epilepsy surgery should include failure of standard medical treatment protocols for SE, definition of epileptogenic zones (EZ) by EEG, semiology, and neuroimaging studies & performance of epilepsy surgery by experienced neurosurgeons.
- |||||||||| lacosamide / Generic mfg.
Lennox-gastaut Lacosamide Efficacy: Case Report (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2261;
Although there is better tolerability of clobazam (CLB) compared to short acting BZDs, its effect in LGS specifically is poorly understood... Case: We have a 16 yo M with LGS who presented with acute repetitive generalized tonic seizures secondary to suboptimal medication adherence on dual regimen of levetiracetam (LEV) and lamotrigine (LTG)...He had poor response to initial abortive BZDs, fosphenytoin and VPA loads and was ultimately preemptively intubated and placed on a midazolam drip with escalating doses (to maximum of 20 mg/hr)...However, he remains at elevated risk for SUDEP and is undergoing surgical evaluation for Vagal Nerve Stimulator placement.
- |||||||||| Fycompa (perampanel) / Eisai, Catalyst Pharma, Epidiolex (cannabidiol) / Jazz, Xcopri (cenobamate) / SK Bio
Implementing an Interactive Dashboard to Evaluate Medication Side Effects in People Living with Epilepsy (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2213;
Commonly used drugs were levetiracetam (Keppra, Roweepra, Spritam), lamotrigine (Lamictal), and Lacosamide (Vimpat), while newer less frequently used drugs were cenobamate (Xcopri), cannabidiol (Epidiolex), and perampanel (Fycompa). This interactive dashboard can help screen PWEs to identify those with side effects to certain medications, which can differ by degree of seizure control; this could allow for more informed decision-making on balancing side effects and seizure control for future medication trials.
- |||||||||| lacosamide / Generic mfg., levetiracetam / Generic mfg.
Ictal Asystole During Focal Impaired Awareness Seizures: A Case Report (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2192;
Ictal asystole has been managed thus far with antiepileptic medications and pacemakers to minimize morbidity. In terms of the significance of these findings, this case report demonstrates that patients with ictal asystole require close monitoring with both neurology and cardiology, and that guidelines for optimal medical management after pacemaker placement are needed to reduce seizure recurrence without exacerbating the risk of asystole.
- |||||||||| levetiracetam / Generic mfg., clobazam / Generic mfg.
Epilepsy in Female Carriers of Dystrophinopathies (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2125;
Female carriers of DMD and BMD may be at a higher risk for developmental delay and epilepsy compared to the general population. Larger studies are needed to better understand this association.
- |||||||||| Xcopri (cenobamate) / SK Bio
Efficacy of Cenobamate in the Treatment of Refractory Seizures in Patients with Chromosome 8 Partial Deletion: A Case Report (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2111;
Our report aims to emphasize the therapeutic potential of Cenobamate in managing refractory seizures, particularly in patients with genetic abnormalities such as Chromosome 8p deletion. These results highlight the need for continued investigation into Cenobamate's efficacy and safety profile, as well as its role in optimizing seizure management strategies for this patient population.
- |||||||||| lamotrigine liquid oral suspension / OWP Pharma
Differential Cerebral Cortical Thickness in Juvenile Myoclonic Epilepsy and Epilepsy with Generalized Tonic (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2098;
The thickness variation of the neocortex could be a potential radiologic biomarker for distinguishing JME and GTCA and could provide an explanation of the clinical differences. Limitations are small patient size, not considering left-right dominance, and subcortical and cerebellar structures.
- |||||||||| levetiracetam / Generic mfg.
Decreasing Use of Lamotrigine Monotherapy for Pediatric Epilepsy in the United States (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2083;
This trend in prescribing practices is more prominent in racial and ethnic minorities and those with higher social vulnerability. Data used in this study came from Epic Cosmos, a data set created in collaboration with a community of Epic Health systems representing more than 249 million patient records from over 1,412 hospitals from all 50 states and Lebanon.
- |||||||||| lamotrigine liquid oral suspension / OWP Pharma
Decoding the Relationship Between Anti-seizure Medication Levels and Neural Excitability (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_2082;
The consistent importance of aperiodic features supports the hypothesis that ASMs modulate the E/I balance and EEG background activity. We will expand our dataset to include patients with epilepsy to determine whether these findings generalize across both non-epileptic and epileptic populations to assess how these E/I changes relate to seizure suppression.
|
